[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577989":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":32,"studyPopulation":33,"armGroups":34,"interventions":39,"overallOfficials":28,"centralContacts":45,"locations":54,"responsibleParty":98,"collaborators":28,"id":100,"slug":28,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":28,"enrollmentInfo":109,"targetDuration":112,"studyType":113,"phases":28,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":57,"whyStopped":28,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"RenovoRx","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":28},[9,13],{"measure":10,"description":11,"timeFrame":12},"Safety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.","Number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.","From the time of the first treatment, until 30 days after the last treatment",{"measure":14,"description":15,"timeFrame":12},"Performance of RenovoCath® as assessed by the number of participants experiencing adverse events related to the inter-arterial drug delivery procedure.","Track the performance of RenovoCath® in a real-world setting delivering a variety of therapeutic agents",[17,21,24],{"measure":18,"description":19,"timeFrame":20},"Overall Survival","Evaluate overall survival (OS) in patients diagnosed with solid tumors who undergo localized IA delivery of therapeutic agents via the RenovoCath®","24 months from date of first treatment with IA",{"measure":22,"description":23,"timeFrame":20},"Tumor Response Rate","Assess tumor response, via imaging, in the primary site of application",{"measure":25,"description":26,"timeFrame":27},"Number of participants who are downstaged and have their tumor resected after IA treatment with RenovoCth","The number of participants who received IA treatment with RenovoCath and later receive resection of their tumor","6 months from the date of the first IA treatment",null,{"allocation":28,"interventionModel":28,"interventionModelDescription":28,"primaryPurpose":28,"observationalModel":30,"timePerspective":31,"maskingInfo":28},"CASE_ONLY","PROSPECTIVE","This study will enroll patients diagnosed with solid tumors who are willing to participate in the registry and meet the study enrollment criteria. Participants will be treated with therapeutic agents using RenovoCath® for the approved intended use according to the current country-specific Instructions for Use (IFU). Participants will be followed for survival outcome. Patients may chose to consent to participation in the registry before, during, or after treatment with the RenovoCath® device.\n\nThis observational post-marketing registry study is intended to track the safety and performance of the RenovoCath® device and assess patient survival \u002F clinical outcomes of RenovoCath® in a real-world, clinical, observational setting when used for targeted delivery of therapeutic agents. Up to 1000 patients will be enrolled at up to an estimated 100 sites. Each patient participating in the registry study will have medical record retrievals including past data as of the time of their initial diagnosis through all localized IA administrations of therapeutic agent(s) using RenovoCath®, with continued record retrieval through the end of patient follow-up to record mortality rates. Patient data collection will include prior treatment history. Patients and\u002For their families will be contacted periodically after the treatment(s) to assess survival. It is anticipated that each participating patient's records will be retrieved approximately four times throughout the course of their treatment and follow-up, or retrospectively should patents decide to participate in the registry upon the completion of their treatment or during follow-up. This registry study is expected to continue for six years from study commencement.","Patients will be recruited for the study by treating physicians. Up to 1000 participants may be enrolled at up to an estimated 100 study sites. Participants will have been diagnosed with solid tumors with histological or cytological confirmation and may have been treated previously with chemotherapy, radiation therapy, or other modalities.",[35],{"label":36,"type":28,"description":36,"interventionNames":37},"Patients receiving Intra-Arterial treatment with RenovoCath",[38],"Device: RenovoCath®",[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":28},"DEVICE","RenovoCath®","Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.",[36],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":28,"email":50},"Leesa M Gentry","CONTACT","650-284-4433","lgentry@renovorx.com",{"name":52,"role":48,"phone":49,"phoneExt":28,"email":53},"Nicolette G Keller","nkeller@renovorx.com",[55,72,85],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Baptist Health South Florida","RECRUITING","Coral Gables","Florida","33143","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-80.26838,25.72149,{"lat":67,"lon":66},[70],{"name":71,"role":48,"phone":28,"phoneExt":28,"email":28},"Dr. Gandhi",{"facility":73,"status":57,"city":74,"state":75,"zip":76,"country":61,"countryCode":62,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"University of Pennsylvania Medical Center","Pittsburgh","Pennsylvania","15213",{"type":64,"coordinates":78},[79,80],-79.99589,40.44062,{"lat":80,"lon":79},[83],{"name":84,"role":48,"phone":28,"phoneExt":28,"email":28},"Dr. Novelli",{"facility":86,"status":57,"city":87,"state":88,"zip":89,"country":61,"countryCode":62,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"The University of Vermont Medical Center","Burlington","Vermont","05401",{"type":64,"coordinates":91},[92,93],-73.21207,44.47588,{"lat":93,"lon":92},[96],{"name":97,"role":48,"phone":28,"phoneExt":28,"email":28},"Dr. O'Neill",{"type":99,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100577989",false,"NCT06805461","PumaRx Registry Trial","A Multi-Center, Observational, Post-Marketing, Registry Study Following Patients With Solid Tumors Treated With Therapeutic Agents Via Localized Intra-Arterial Delivery Using the RenovoCath® Catheter","PumaRx","Eligibility Criteria:\n\n1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure\n2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records","ALL","18 Years",{"count":110,"type":111},1000,"ESTIMATED","36 Months","OBSERVATIONAL","This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.",[116],"Solid Tumors",[118],"Intra-Arterial Catheter","2026-03-25",{"date":121,"type":122},"2026-03-30","ACTUAL",{"date":124,"type":122},"2025-08-01",{"date":126,"type":111},"2029-09-03",{"name":5,"class":6},3]